BeOne Medicines, formerly BeiGene, is a global oncology company that discovers, develops, and delivers cancer medicines. Founded in 2010 and employing approximately 12,000 people across six continents, it operates an integrated model spanning drug discovery, drug development, clinical development and biotech R&D. Its research organisation includes more than 1,200 research scientists.
The company has three internally discovered, approved medicines - BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab) and pamiparib - which between them hold regulatory approvals in over 80 countries. More than 30 investigational medicines are in development, and the company has initiated over 180 clinical trials globally, enrolling over 30,000 patients.
BeOne Medicines works across the oncology, pharmaceuticals and biotechnology verticals, with the stated mission of making breakthrough medicines accessible to patients worldwide and of accelerating the pace of cancer research. Its stated aim since founding has been to transform cancer treatment.
